Last updated on June 2012

GOG 0213: A Phase III, Randomized, Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer. NCI-SUPPLIED AGENTS: BEVACIZUMAB.


Brief description of study

GOG 0213: A Phase III, Randomized, Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer. NCI-SUPPLIED AGENTS: BEVACIZUMAB.

Detailed Study Description

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00565851?term=gog+0213&rank=1

Clinical Study Identifier: TX135801

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Patricia Green

Memorial University Medical Center
Savannah, GA USA
  Connect »